Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Payables (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Payables for 7 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 95.63% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 95.63% increase, with the full-year FY2024 number at $1.1 million, down 48.81% from a year prior.
  • Payables was $2.1 million for Q3 2025 at Vivos Therapeutics, up from $1.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.5 million in Q1 2024 to a low of $644000.0 in Q3 2022.
  • A 5-year average of $1.4 million and a median of $1.3 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: surged 137.27% in 2023, then plummeted 51.74% in 2025.
  • Vivos Therapeutics' Payables stood at $920000.0 in 2021, then skyrocketed by 53.37% to $1.4 million in 2022, then soared by 52.02% to $2.1 million in 2023, then crashed by 48.81% to $1.1 million in 2024, then surged by 91.53% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Payables are $2.1 million (Q3 2025), $1.8 million (Q2 2025), and $1.2 million (Q1 2025).